Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
Episode Ep 133 15 min 21s

Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting

In this podcast episode, listen to Susana Banerjee, MBBS, MA, PhD, FRCP, and Mansoor Raza Mirza, MD, share their thoughts on trials of interest for ovarian and cervical cancer presented at the IGCS 2022 Annual Global Meeting, including results from the highly anticipated CALLA trial, final OS analyses for ARIEL3, outcomes by previous lines of therapy from SOLO3, and results from the retrospective NeCTuR trial of topotecan, paclitaxel, and bevacizumab in neuroendocrine cervix cancer.

You May Also Like

Community discussion